Alembic Pharmaceuticals has reported results for first quarter ended June 30, 2023 (Q1FY24).
The company has reported net profit at Rs 97.53 crore for the quarter under review as against net loss of Rs 49.39 crore for the same quarter in the previous year. Total income of the company increased by 14.12% at Rs 1,344.12 crore for Q1FY24 as compared Rs 1,177.79 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported net profit of Rs 120.60 crore for the first quarter ended June 30, 2023 as against net loss of Rs 65.88 crore for the same quarter in the previous year. Total income of the company increased by 18.57% at Rs 1,497.81 crore for Q1FY24 as compared Rs 1,263.22 crore for the corresponding quarter previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |